We are excited to announce that Biocytogen will participate in the 6th Annual Gulf Coast Consortia (GCC) Innovative Drug Discovery and Development Conference: Pioneering New Approaches for Healthcare Innovation. Join us on May 6–7, 2025, in Houston, Texas, for this premier bioscience research event, where experts from academia, biotech, and pharmaceutical industries will convene to discuss the latest drug discovery and development advancements. Let’s connect and push the boundaries of healthcare together—see you in Houston!
What is the 6th Annual GCC Innovative Drug Discovery and Development Conference?
The GCC Innovative Drug Discovery and Development Conference is a leading event that brings together top scientists, biotech leaders, and pharmaceutical pioneers to explore groundbreaking research and emerging technologies shaping the future of drug discovery. Attendees will be able to engage with thought leaders, discover novel approaches, and gain insights into the evolving landscape of healthcare innovation.
Event Overview
Date: May 6, 2025 · 9:00 AM – May 7, 2025 · 5:00 PM CDT
Venue: BioScience Research Collaborative Auditorium and Event Hall. 6500 Main St, Houston, TX 77030
Event Schedule
The GCC Innovative Drug Discovery and Development Conference in Houston, Texas will showcase a remarkable array of speakers and topics. For a comprehensive look at the daily schedule, including session times and detailed information on each presentation, please refer to Agenda 6th Annual Gulf Coast Consortia Innovative Drug Discovery and Development Conference: Pioneering New Approaches for Healthcare Innovation
About BIOCYTOGEN
Biocytogen is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA(Boston, San Francisco), and Germany (Heidelberg).
We look forward to seeing you at the 6th Annual GCC Innovative Drug Discovery and Development Conference in Houston, Texas
